Oncology

Overall survival rates for various cancers differed by race.

Knowledge gaps exist around the timing of pneumonitis onset in patients treated with checkpoint inhibitors.

The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

A short supply of cisplatin and carboplatin is forcing health care providers to find less effective alternative treatments.

From compounding to cleaning, oncology pharmacy technicians take on key responsibilities in infusion centers.

From explaining how medications work and should be taken to reviewing potential adverse effects and financial details, pharmacists are crucial resources for patients undergoing treatment for skin cancer.

A new survey found that neither generation is particularly good at maintaining healthy sun habits, and have low skin cancer awareness.

Approximately 8000 to 9000 U.S. patients would be eligible for this combination, intended for patients with locally advanced or metastatic urothelial cancer (la/mUC).

Off-label drug combinations are increasingly being used in cancer treatments, but there is the potential for overlapping or additive toxicities, explained a speaker at the 2023 HOPA Annual Conference.

During a session at the 2023 HOPA Annual Conference, Rebecca Champion, PharmD, BCOP, highlighted new therapies in the market for hematologic malignancies with a focus on bispecific antibodies and chimeric antigen receptor T-cell therapies.

Precision oncology is a growing, changing field.

The risk of developing breast cancer was greater in women who are currently using or recently used progestogen-only contraceptives, a recent study showed.

The drug, called Lumisight, is an optical imaging agent that detects cancerous tissue during initial lumpectomy to allow for a more complete resection. An NDA has been submitted to the FDA.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

A combination of dabrafenib with trametinib was approved by the FDA for treatment of pediatric patients 1 year and older with low-grade glioma & BRAF V600E mutation who require systemic therapy.

Treating myelofibrosis with Jakafi earlier has shown promise in improving both survival and symptom burden

Pharmacy technicians can provide a great amount of value for patients navigating the financial toxicity of cancer treatment.

The FDA agreed to review a supplemental Biologics License Application for Opdivo to treat stage 2B or C, fully resected melanoma.

The expansion was based on 4-year data from the monarchE study.

The safety of gel manicures is under renewed scrutiny after a new study suggested they can cause DNA damage

The PDFUA date for the drug is October 13, 2023.

Collections of oncology drugs in 13 states are being redistributed to patients in need.

Advocates can specialize in order to provide more targeted assistance for patients.

President Biden's 2023 State of the Union address highlighted some key areas of health care in which he hopes to make progress.

Sacituzumab govitecan significantly improved overall survival over the comparator chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer who had received prior treatment.